<?xml version="1.0" encoding="UTF-8"?>
<p>A trial of lenalidomide, bendamustine and rituximab recently documented a complete response rate of 64%, with molecular MRD negativity reached in 34% patients. Toxicity, however, was greater than with the RiBVD regimen, with infectious grade 3-5 toxicities seen in 42% of the 51 recruited patients.
 <sup>
  <xref rid="b13-1040138" ref-type="bibr">13</xref>
 </sup> Two large phase III trials of BR ± ibrutinib or BR ± ACP196 (acalabrutinib) are still ongoing and results are pending.
</p>
